

POWER OF ATTORNEY
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**POWER OF ATTORNEY BY ASSIGNEE
AND EXCLUSION OF INVENTOR(S) UNDER 37 C.F.R. 3.71
WITH STATEMENT UNDER 37 C.F.R. 3.73(b)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned assignee of the patents and patent applications listed on Attachment A, hereby appoints Practitioners of Jones Day associated with Customer Number 20583, which mailing address is Jones Day, 222 East 41st Street, New York, New York 10017, as its attorneys to prosecute these applications and to transact all business in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorney(s) in accordance with the provisions of 37 C.F.R. 3.71.

Please direct all correspondence for this application to Customer no. 20583.

Statement Under 37 C.F.R. 3.73(b)

L'UNIVERSITÉ MONTPELLIER II states that it is:

the assignee of the entire right, title, and interest; or
 an assignee of less than the entire right, title and interest.

in the patent applications/patent identified above by virtue of:

An assignment agreement dated March 4, 2009. The assignment agreement was recorded in the United States Patent and Trademark Office on May 6, 2009 at Reel 022644, Frame 0923, or for which a copy thereof is attached.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

ASSIGNEE: L'UNIVERSITÉ MONTPELLIER II

Date: 26/05/2009 Signature: _____

Typed Name: DANIÈLE HÉRIN

Position/Title: PRESIDENT



Attachment A

Joint Dkt. C.A.M	Bucket No.	Status R&T No.	Inv.	Inv.	Serial No.	Filed	Title
417451-888016	11874-016-988	1017 US PROV	Gosselin, G. Sommadossi, J.-P. Mousa, A. Pierre, C. Beurain-Prud, S. Duchan, D. LaColla, P.	600932,351	6/28/02		2' and 3' Nucleoside Products for Treating Hepatitis C Virus
417451-999016	11874-016-999	1017 US	11874-016-988 11874-016-988 11874-016-988	11659,298	6/27/03		2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999047	11874-047-599	1017 US CON 1	CON of 11874-016-999	Gosselin, G. Stover, R. LaColla, P. Sommadossi, J.-P.	11005,471	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999048	11874-048-599	1017 US CON 2	CON of 11874-016-999	Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005,442	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999049	11874-049-599	1017 US CON 3	CON of 11874-016-999	Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005,466	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999050	11874-050-599	1017 US CON 4	CON of 11874-016-999	Gosselin, G. LaColla, P. Sommadossi, J.-P.	11005,440	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999051	11874-051-599	1017 US CON 5	CON of 11874-016-999	Gosselin, G. Stover, R. LaColla, A. Sommadossi, J.-P.	11005,443	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999052	11874-052-599	1017 US CON 6	CON of 11874-016-999	Gosselin, G. LaColla, A. Sommadossi, J.-P.	11005,446	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999053	11874-053-599	1017 US CON 7	CON of 11874-016-999	Gosselin, G. LaColla, A. Sommadossi, J.-P.	11005,472	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections
417451-999054	11874-054-599	1017 US CON 8	CON of 11874-016-999	Gosselin, G. LaColla, A. Sommadossi, J.-P.	11005,444	12/6/04	2' and 3' Nucleoside Products for Treating Flaviviridae Infections

Joint Inv. & C.A.N.	Descript. No.	Serial No.	Issue Date	Expiry	Link
417451-880255	11874-052-888 PROV	603923,50	6/28/02		Modified 2' and 3' Nucleoside Prodrugs for Treating Hepatitis C Virus
417451-990035	11874-055-999	10668,407	6/27/03		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-990036	11874-056-999 CON 1	11005,445	12/6/04		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-990037	11874-057-999 CON 2	11005,473	12/6/04		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-990058	11874-058-999 CON 3	11005,468	12/6/04		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-990059	11874-059-999 CON 4	11005,467	12/6/04		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-990060	11874-060-999 CON 5	11005,470	12/6/04		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-990061	11874-061-999 CON 6	11005,447	12/6/04		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections
417451-990062	11874-062-999 CON 7	11005,441	12/6/04		Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviridae Infections

Janus Dux CAN	Docket No.	Identif. Ref. No.	Issue Date/ Released	Inventor	Serial No.	Filed	Title
417451-599663	11874-463-999	1018 US CON 8	11/08/03-05-999	LaColla, P. Goselin, G. Sommerski, J.-P.	11/005,469	12/004	Modified 7- and 3'-Nucleoside Prodrugs for Treating Flaviviride Infections
417451-599190	11874-190-999	1018 US	11/06/03-1874- 05-999	LaColla, P. Goselin, G. Sommerski, J.-P.	12/131,868	5/2008	Modified 2' and 3' Nucleoside Prodrugs for Treating Flaviviride Infections
417451-599205	11874-216-999	1031 US	11/07/04-016-888	Sommerski, J.-P. La Colla, P. Goselin, G.	10/601,909	6/27/03	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviride Infections
417451-599086	11874-086-999	1031 US CON 1	11/07/04-130-888 11/07/04-086-999	Sommerski, J.-P. La Colla, P. Goselin, G.	11/016,928	9/6/06	2'-C-Methyl-3'-O-L-Valine Ester Riboflavinoyl Cytidine for Treatment of Flaviviride Infections
417451-581077	11874-477-888	1040 US PROV		Goselin, G. LaColla, P. Seth, F. Stover, R. Duhme, D. Leroy, F.	60/582,182	6/23/04	5'-Azido-7'-Desaziquine Derivatives for Treating Flaviviride
417451-5990077	11874-477-999	1040 US	11/07/04-077-888	Goselin, G. LaColla, P. Seth, F. Stover, R. Duhme, D. Leroy, F.	11/164,498	6/23/05	5'-Azido-7'-Desaziquine Derivatives for Treating Flaviviride